Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of ...

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...

Breckenridge Pharmaceutical, Inc., -the U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States, - announced today that the Food and ...

Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...